We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




A Potential Point-of-Care Method for the Diagnosis of Sepsis

By LabMedica International staff writers
Posted on 21 Nov 2019
As part of the effort to create better methods to detect and treat sepsis, researchers developed a technique that enables measurement of the activation and function of white blood cells.

Sepsis is caused by an inflammatory immune response triggered by an infection. More...
It is a life-threatening condition that arises when the body's response to infection causes injury to its own tissues and organs. Common signs and symptoms include fever, increased heart rate, increased breathing rate, and confusion. There may also be symptoms related to a specific infection, such as a cough with pneumonia, or painful urination with a kidney infection. In the very young, old, and people with a weakened immune system, there may be no symptoms of a specific infection and the body temperature may be low or normal, rather than high.

Current testing and diagnostic approaches fail to provide the precise and timely information needed to treat sepsis. To correct this, investigators at Brigham and Women's Hospital (Boston, MA, USA) designed a new method, based on microfluidics, which relies on minute channels to separate 50 microliter samples of peripheral blood into fractions comprising either the larger white blood cells or the smaller red blood cells and other elements of the blood.

The size-based microfluidic method was combined with novel isodielectric separation technology - developed by colleagues at the Massachusetts Institute of Technology (Cambridge, MA) - which measured cellular electrical activity. This method detected changes that occurred when white blood cells became activated and could distinguish patients with and without inflammation, such as in sepsis.

The investigators used the system to assess leukocyte phenotype and function over a period of seven days in serial samples from 18 hospitalized patients with sepsis and 10 healthy subjects.

Results revealed that the sepsis samples had significantly higher levels of CD16dim and CD16− neutrophils and CD16+ “intermediate” monocytes, as well as significantly lower levels of neutrophil-elastase release, O2 production, and phagolysosome formation. Repeated sampling of sepsis patients over seven days showed that leukocyte activation (measured by isodielectric separation) and leukocyte phenotype and function were significantly more predictive of the clinical course than complete-blood-count parameters.

"Our idea was to develop a point-of-care diagnostic test that, instead of focusing on the white blood cell count, would inform us about white blood cell activation state and function," said senior author Dr. Bruce Levy, chief of the division of pulmonary and critical care medicine at Brigham and Women's Hospital. "It has been exciting for us, as translational scientists, to work on a solution with outstanding bioengineer colleagues. Together, we are able to address a truly important clinical problem."

The potential use of the leukocyte function test to diagnose sepsis was described in the November 11, 2019, online edition of the journal Nature Biomedical Engineering.

Related Links:
Brigham and Women's Hospital
Massachusetts Institute of Technology



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.